Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Study Data

Author: Benzinga Newsdesk | March 25, 2025 08:13am
  • Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease
  • Simufilam continued to demonstrate an overall favorable safety profile
    • Cassava's Alzheimer's disease development program with simufilam will be completely discontinued by the end of Q2 2025
       

Posted In: SAVA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist